Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014

launch Related Market Assessment Reports

• Chronic Myeloid Leukemia – Current Treatment – Detailed, Expanded Analysis (US)

  July 2023

  The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…

• Chronic Myeloid Leukemia – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)

  July 2023

  Key benefits and uses
  Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting
  Drill down into physicians’ treatment sequences and understand whom to position…

• Chronic Myeloid Leukemia – Epidemiology – Epidemiology Data Slicer

  December 2022

  EPI Data Slicer

• Ulcerative Colitis & Crohn’s Disease | Access and Reimbursement | Brazil/Mexico | 2017

  February 2022

• Chronic Myeloid Leukemia – Epidemiology – Emerging Markets Data

  January 2020

  Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…